Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website
Hamlet BioPharma, ticker HAMLET B, the innovative pharmaceutical company, which develops new therapies against cancer and infections, is pleased to inform that the CEO World Magazine, renowned for its focus on high-level executives and influential business leaders, has featured Hamlet BioPharma in their latest Company Spotlight. They highlight Hamlet’s recent clinical trials and innovative approach merging groundbreaking research with a strong business vision.
With its vast readership of 12.4 million CEOs, CFOs, and decision-makers worldwide, the feature interview with Chairman, Professor Catharina Svanborg, underscores Hamlet BioPharma’s role in advancing treatments for cancer, tuberculosis and other infections.
CEO World Magazine is one of the leading business publications in the world read by CEOs, senior management, high-net-worth individuals and investors, and features in-depth reporting across multiple industries. It provides essential insights into global business trends, executive leadership, and transformative ideas from prominent CEOs and business innovators.
Read the article here: https://ceoworld.biz/2024/10/29/interview-with-catharina-svanborg-of-hamlet-biopharma/#google_vignette
In addition, Hamlet BioPharma has been featured by Pulse 2.0, that specializes in business and tech industry news, targeting leaders and professionals who seek updates on innovative trends and company growth stories. Pulse 2.0, known for its insightful analysis on technology and business innovation also featured Hamlet BioPharma’s recent clinical trials and the strategic merger between Hamlet Pharma with Selectimmune Pharma. The magazine profiles changemakers, visionaries and future-forward companies and organizations.
Read the article here: https://pulse2.com/hamlet-biopharma-profile-professor-catharina-svanborg-interview/.
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49, [email protected]
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
